1. Intralesional interleukin‐2 augmentation therapy in treatment‐refractory melanoma.
- Author
-
Le, Stephanie T., Ji‐Xu, Antonio, Liakos, William, Toussi, Atrin M., Cheng, Michelle Y., Ma, Chelsea, Wang, Elizabeth A., Wilken, Reason, Boddu, Sucharita, Downing, Lauren, Kao, Jason, Davis, Julian R., Monjazeb, Arta M., Fung, Maxwell A., Konia, Thomas H., Maverakis, Emanual, and Kirane, Amanda R.
- Subjects
INTERLEUKIN-2 ,ALPHA 1-antitrypsin deficiency ,VITILIGO ,MELANOMA ,SENTINEL lymph node biopsy - Abstract
For locally invasive/in-transit cutaneous melanoma, we have advocated combination therapy with intralesional interleukin (IL)-2 and topical imiquimod and tretinoin, which can completely eradicate melanoma in a T cell-dependent fashion.1,2 However, its ability to augment systemic therapies remains uninvestigated. (H) PET/CT after 1 month of treatment with BRAF/MEK inhibitor therapy showing several new mediastinal metastases indicative of progressive disease. Advances in immunotherapy have expanded the armamentarium of treatments for metastatic melanoma. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF